A	doxorubicin
ACT	adriamycin, cyclophosphamide, and paclitaxel (taxol)
AR	androgen receptor
AUC	area under the curve
BC	Breast Cancer
Bev	bevacizumab
BL1	basal-like 1
BL2	basal-like 2
BLIA	basal-like immune-activated
BLIS	basal-like immunosuppressed
C	cyclophosphamide
CBR	clinical benefit rate
DC	ductal carcinoma
dd	dose-dense
ddAC	Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide
E	epirubicin
ECM	extracellular matrix
ER	estrogen receptor
FUSCC	Fudan University Shanghai Cancer Center
G	gemcitabine
GO	Gene Ontology
HER2	human epidermal growth factor receptor 2
IM	immunomodulatory
LAR	luminal androgen receptor
lncRNAs	long noncoding RNAs
M	mesenchymal
MES	mesenchymal-like subtype
MSL	mesenchymal stem-like
MUC1	cell-surface mucin
N/A	not applicable
nP	nab-Paclitaxel
NPLD	non-pegylated liposomal doxorubicin
NST	neoadjuvant systemic treatment
OS	overall survival
P	paclitaxel
pCR	pathological complete response
PDGFRα	platelet-derived growth factor receptor α
PR	progesterone receptor
RCTs	randomized controlled trials
RFS	relapse-free survival
RT	radiotherapy
T	docetaxel
TGF	transforming growth factor
TNBC	Triple-negative breast cancer